<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cardiac arrhythmias due to digoxin toxicity
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cardiac arrhythmias due to digoxin toxicity
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cardiac arrhythmias due to digoxin toxicity
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ary L Goldberger, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Evan Schwarz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 20, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac glycosides (digitalis preparations including
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         and digitoxin) are used clinically in two situations: heart failure due to systolic dysfunction, and in certain supraventricular tachyarrhythmias [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The ability to enhance cardiac contractility and modulate neurohumoral activation can lead to symptomatic improvement in systolic heart failure, although it is unclear if survival is prolonged even in carefully selected patients with low therapeutic serum levels. (See
         <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">
          "Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Digoxin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         also slows conduction through the atrioventricular (AV) junction (node) by increasing cardiac vagal tone modulation. It may also have a sympathoinhibitory effect in therapeutic doses. As a result, it is sometimes used (usually adjunctively with beta blockers or calcium channel blockers) for controlling the ventricular response in atrial fibrillation and atrial flutter when there is excessively rapid transmission of stimuli from the atria to the ventricles through the AV junction. (See
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1067.html" rel="external">
          "Control of ventricular rate in atrial flutter"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         may also be effective in the treatment of certain types of reentrant paroxysmal supraventricular tachycardia involving the AV node.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         toxicity continues to be an important clinical problem which may be life-threatening [
         <a href="#rid2">
          2
         </a>
         ]. The incidence of digoxin excess and toxicity, along with the potential associated arrhythmias, are presented here. The management of digoxin intoxication, including the treatment of cardiac arrhythmias associated with digoxin toxicity, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/319.html" rel="external">
          "Digitalis (cardiac glycoside) poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/983.html" rel="external">
          "Cardioversion for specific arrhythmias", section on 'Cardioversion in patients with digitalis toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INCIDENCE OF DIGOXIN TOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Technical advances and changes in practice patterns have lowered the incidence of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         overdose in patients receiving chronic therapy [
         <a href="#rid3">
          3
         </a>
         ]. However, digoxin toxicity remains an important clinical syndrome in which potentially fatal cardiac arrhythmias can occur [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/319.html" rel="external">
          "Digitalis (cardiac glycoside) poisoning"
         </a>
         .)
        </p>
        <p>
         In a large study of patients with congestive heart failure who were treated with
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         , definite digoxin toxicity occurred in 0.8 percent and possible toxicity in another 4 percent [
         <a href="#rid5">
          5
         </a>
         ]. Digoxin toxicity was also reported in 4 percent of patients in a 1998 study [
         <a href="#rid6">
          6
         </a>
         ]. In spite of efforts to educate prescribers to use lower digoxin doses (in heart failure patients) with a goal of lower plasma digoxin levels, the frequency of emergency department visits related to digoxin toxicity has remained relatively unchanged [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PLASMA DIGOXIN LEVELS ASSOCIATED WITH TOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Life-threatening digoxin-induced arrhythmias and other toxic manifestations occur at substantially increasing frequency as the plasma
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         concentration rises above 2.0 ng/mL (2.6 nmol/L). However, clinicians should be aware that signs of toxicity may occur at levels below 1.3 to 1.5 ng/mL (1.7 to 1.9 nmol/L), and such toxicity is more likely in the presence of one or more comorbid conditions (eg, hypokalemia, hypomagnesemia, hypercalcemia, myocardial ischemia). Hypokalemia is a particularly important risk factor that can promote digoxin-induced arrhythmias. Patients with heart failure who are older than 65 years are also at increased risk [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/319.html" rel="external">
          "Digitalis (cardiac glycoside) poisoning"
         </a>
         .)
        </p>
        <p>
         Retrospective analysis of data from the large digitalis investigation group (the DIG trial) revealed that serum
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         levels ranging from 1.2 to 2.0 ng/mL (1.5 to 2.6 nmol/L) were associated with an excess mortality versus placebo in women with heart failure [
         <a href="#rid9">
          9
         </a>
         ]. Therefore, we recommend maintaining trough digoxin levels at the lower range (eg, between 0.5 and 0.8 ng/mL [0.6 to 1.0 nmol/L]) in both male and female patients to help minimize toxicity [
         <a href="#rid10">
          10,11
         </a>
         ].
        </p>
        <p>
         The safety and effectiveness of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         in patients with atrial fibrillation with and without chronic heart failure also continue to generate controversy and conflicting findings [
         <a href="#rid12">
          12,13
         </a>
         ]. Until more definitive prospective clinical trial data are available [
         <a href="#rid13">
          13
         </a>
         ], serum digoxin concentrations should be maintained within the low therapeutic range (0.5 to 0.8 ng/mL [0.6 to 1.0 nmol/L]), with careful monitoring of renal function and serum potassium concentrations.
        </p>
        <p>
         Plasma
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         levels should be measured at least 6 hours and preferably 12 or more hours after the last dose since this is the time required for attainment of the steady state due to gradual distribution through the extravascular space. (See
         <a class="medical medical_review" href="/z/d/html/1051.html" rel="external">
          "Treatment with digoxin: Initial dosing, monitoring, and dose modification"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121087.html" rel="external">
          "Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Digoxin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          MECHANISMS OF CARDIAC TOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism(s) by which
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity promotes the development of arrhythmias remain incompletely understood. Two general categories have been described: enhanced ectopy with tachyarrhythmias, and bradyarrhythmias [
         <a href="#rid14">
          14
         </a>
         ]. Digoxin can affect cardiac tissue in a number of ways which may result in toxicity:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         directly inhibits the ATPase dependent sodium-potassium pump, increasing intracellular sodium. This, in turn, reduces the activity of a sodium-calcium exchanger that normally extrudes calcium from the cell [
         <a href="#rid15">
          15
         </a>
         ]. The resulting increase in intracellular calcium is responsible for the positive inotropic action of digoxin. The fluxes in calcium can also have electrophysiologic effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac glycosides activate ryanodine receptors, which could contribute to increased calcium release from the sarcoplasmic reticulum and could play a role in the inotropic action of glycosides in vivo [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         increases vagal tone through central and peripheral effects; however, at excess levels, digoxin may augment cardiac sympathetic tone [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         As a result of the effect on intracellular calcium concentrations and vagal tone, high levels of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         can have a variety of effects that facilitate the development of arrhythmias. They can enhance and depress automaticity, induce triggered membrane activity (especially delayed afterdepolarizations), increase or decrease excitability, slow conduction, and alter refractoriness, also producing conditions conducive to the development of reentrant arrhythmias.
        </p>
        <p class="headingAnchor" id="H13658052">
         <span class="h1">
          DIGOXIN-INDUCED ARRHYTHMIAS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A wide range of arrhythmias occurring at almost any intracardiac location can be seen with
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity, depending in part upon the age of the patient and the state of the myocardium. Accentuation of vagal effects and resulting bradyarrhythmias are more commonly seen in younger, healthier individuals. Conversely, patients with severe cardiac disease and concurrent digoxin toxicity are more susceptible to ventricular ectopy and tachyarrhythmias. (See
         <a class="medical medical_review" href="/z/d/html/2120.html" rel="external">
          "ECG tutorial: Miscellaneous diagnoses", section on 'Digitalis toxicity'
         </a>
         .)
        </p>
        <p>
         There are, however, some arrhythmias that are generally not directly induced by
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         . Atrial flutter, atrial fibrillation, and Mobitz type II second degree AV block are the least likely of all the arrhythmias to be caused by digoxin toxicity. However, superimposed digoxin toxicity may occur in these settings, for example leading to an excessively slow or regularized ventricular response in atrial fibrillation, or increased ventricular ectopy.
        </p>
        <p>
         The arrhythmias associated with
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity will be discussed according to their myocardial site of origin, including the sinoatrial nodal tissue, atrial myocardium, atrioventricular nodal tissue, and ventricular myocardium.
        </p>
        <p class="headingAnchor" id="H13658144">
         <span class="h2">
          Sinus bradycardia, tachycardia, block, and arrest
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effect of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         and digoxin toxicity on the sinoatrial (SA) node is often difficult to determine because of both indirect and direct actions. As an example, improved hemodynamics in heart failure usually results in a fall in heart rate due to alterations in autonomic balance. Alternatively, sinus bradycardia may also be one of the earliest signs of digoxin excess.
        </p>
        <p>
         Cardiac glycosides have no direct effect on slowing automaticity in the isolated SA node or in the transplanted human heart [
         <a href="#rid18">
          18,19
         </a>
         ]. However, the diseased SA node may be quite sensitive to cardiac glycosides, resulting in sinus bradycardia and SA nodal block [
         <a href="#rid5">
          5,20-22
         </a>
         ]. Animal and human studies suggest that the slowing of the heart rate in this setting is due both to increased vagal tone (mediated by hypersensitization of carotid sinus baroreceptors, central stimulation, increased vagal traffic, and possible potentiation of the effect of acetylcholine on the SA node) and to sympatholytic activity.
        </p>
        <p>
         While most commonly sinus bradycardia is seen, the sinus pacemaker may accelerate in the presence of excess
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         . Both adrenergic stimulation [
         <a href="#rid18">
          18,23-25
         </a>
         ] and direct stimulation of the SA node may contribute to this response [
         <a href="#rid26">
          26-28
         </a>
         ].
        </p>
        <p>
         Toxic levels of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         can also result in SA nodal block  (
         <a class="graphic graphic_waveform graphicRef68081 graphicRef54936" href="/z/d/graphic/68081.html" rel="external">
          waveform 1A-B
         </a>
         ) or even nodal arrest. (See
         <a class="medical medical_review" href="/z/d/html/894.html" rel="external">
          "Sinoatrial nodal pause, arrest, and exit block"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13658391">
         <span class="h2">
          Ectopic atrial tachycardia with block
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic concentrations of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         have little effect on atrial tissue, but toxic levels may result in an ectopic atrial tachycardia, often with 2:1 AV block. Animal studies suggest that the atrial tachycardia is probably mediated by increased automaticity in the atrium and/or delayed afterpotentials, often occurring near and perhaps sometimes within the SA node [
         <a href="#rid27">
          27,29,30
         </a>
         ]. The AV block probably results from the rapid atrial rate, as well as the vagotonic activity and a direct effect of digoxin on AV nodal conduction (see below).
        </p>
        <p>
         Also referred to as "paroxysmal" (ectopic) atrial tachycardia (PAT) with AV block, this arrhythmia is strongly suggestive of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity in patients taking this medication or in cases of suspected overdose. However, the arrhythmia is typically not paroxysmal when induced by digoxin; rather, it is a persistent arrhythmia until specific therapy is instituted or digoxin levels fall below the toxic range (see
         <a class="medical medical_review" href="/z/d/html/900.html" rel="external">
          "Focal atrial tachycardia", section on 'Treatment'
         </a>
         ). It should be noted that most cases of ectopic atrial tachycardia with block are not due to digoxin excess in contemporary practice.
        </p>
        <p>
         Clinically, up to one-half of patients with nonparoxysmal atrial tachycardia with AV nodal block have a P wave morphology similar to the sinus P wave  (
         <a class="graphic graphic_waveform graphicRef56994" href="/z/d/graphic/56994.html" rel="external">
          waveform 2
         </a>
         ). This observation supports the suggestion in animal studies that the ectopic site is often near, or is perhaps in, the SA node. The remaining cases arise at other sites and typically have an abnormal P wave axis as seen in the ectopic atrial tachycardias.
        </p>
        <p>
         Atrial tachycardia with block may superficially resemble atrial flutter. There are two major distinguishing features between these arrhythmias:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The atrial rate is faster (usually 250 to 350 beats/min) with atrial flutter.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The baseline between P waves is isoelectric in atrial tachycardia with block, while there is a constantly undulating baseline between the flutter waves in atrial flutter.
        </p>
        <p>
        </p>
        <p>
         It is important to distinguish between atrial flutter and atrial tachycardia due to
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         excess since the administration of additional digoxin, which may be an appropriate therapy for atrial flutter, can accelerate the atrial rate in an atrial tachycardia, increasing the degree of AV block and potentially precipitating a more serious digoxin-toxic arrhythmia. (See
         <a class="medical medical_review" href="/z/d/html/1061.html" rel="external">
          "Electrocardiographic and electrophysiologic features of atrial flutter"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13658508">
         <span class="h2">
          Atrial fibrillation and flutter
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         toxicity can occur in patients with atrial fibrillation or flutter, even though these arrhythmias are rarely caused by digoxin. A more important clinical problem is the effect of digoxin toxicity on transmission of atrial stimuli through the AV node in patients with preexisting atrial fibrillation. The electrocardiographic findings vary with increasing degrees of digoxin toxicity and with the possible presence of block above or below the pacemaker  (
         <a class="graphic graphic_waveform graphicRef64396 graphicRef76154 graphicRef55119 graphicRef66940" href="/z/d/graphic/64396.html" rel="external">
          waveform 3A-D
         </a>
         ) [
         <a href="#rid31">
          31
         </a>
         ]. Casual evaluation of such a patient who might have severe digoxin toxicity may lead to the mistaken conclusion that the irregular rhythm is due to persistent AF and the digoxin may be inappropriately continued or the dose even increased.
        </p>
        <p>
         Atrial flutter is rarely, if ever, the result of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         intoxication. However, the diagnosis of atrial flutter may be difficult to establish when, as commonly occurs during digoxin therapy, the atrial flutter has a slow ventricular response, with a rate that overlaps that seen in other supraventricular tachycardias, such as nonparoxysmal atrial tachycardia with a 2:1 AV response due to digoxin intoxication. (See
         <a class="local">
          'Ectopic atrial tachycardia with block'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H13658822">
         <span class="h2">
          Atrioventricular nodal block
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic concentrations of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         decrease the conduction velocity through the AV node and increase the refractoriness of the AV node; this affects the conduction of the normal as well as a premature impulse. These effects are mediated primarily by an increase in vagal tone and, to a lesser degree, a reduction in sympathetic activity [
         <a href="#rid5">
          5,20,21,26,32-35
         </a>
         ]. As a result of this dependence on autonomic balance, digoxin is of little value in controlling the ventricular response in patients who have undergone cardiac transplantation due to the denervated nature of the transplanted heart [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
         AV conduction may be blocked partially or completely by
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         excess.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First degree block (AV conduction delay) – Some degree of PR lengthening may be expected with
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         therapy  (
         <a class="graphic graphic_waveform graphicRef67882" href="/z/d/graphic/67882.html" rel="external">
          waveform 4
         </a>
         ). More marked widening of the PR interval to above 0.2 sec suggests early digoxin toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second degree AV block – With higher levels of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         , first degree AV block may progress to second degree block of the Mobitz type I (Wenckebach) variety  (
         <a class="graphic graphic_waveform graphicRef73051" href="/z/d/graphic/73051.html" rel="external">
          waveform 5
         </a>
         ). By contrast, Mobitz type II second degree AV block is rarely, if ever, induced by digoxin alone. (See
         <a class="medical medical_review" href="/z/d/html/909.html" rel="external">
          "Second-degree atrioventricular block: Mobitz type I (Wenckebach block)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Third degree AV block – Third-degree (complete) heart block and other types of AV dissociation may also occur with
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity  (
         <a class="graphic graphic_waveform graphicRef72863" href="/z/d/graphic/72863.html" rel="external">
          waveform 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/911.html" rel="external">
          "Third-degree (complete) atrioventricular block"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         AV block with
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         is more likely to occur in the presence of atrial fibrillation, an ectopic atrial rhythm, or atrial flutter than during normal sinus rhythm. The reason is that more atrial impulses are present to reach the AV node during these atrial tachyarrhythmias than during slower rates. In atrial fibrillation, a high degree of AV block may occur, resulting in the ventricles being controlled intermittently by a lower junctional or ventricular pacemaker.
        </p>
        <p>
         The ECG findings vary with atrial fibrillation, due to a number of factors, including the possible presence of exit block below the pacemaker. The following additional arrhythmias can be seen with increasing degrees of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity in the presence of atrial fibrillation  (
         <a class="graphic graphic_waveform graphicRef64396 graphicRef76154 graphicRef55119 graphicRef66940" href="/z/d/graphic/64396.html" rel="external">
          waveform 3A-D
         </a>
         ) [
         <a href="#rid31">
          31,36
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A high but not complete degree of AV block in atrial fibrillation will initially lead to single junctional, subjunctional, or ventricular escape beats with a cycle length characteristic of that of the underlying pacemaker. These escape beats recur episodically during a rhythm strip; they can be diagnosed by the demonstration that the recurring longest R-R intervals have a constant cycle length.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A higher degree of AV or third degree block results in so few atrial impulses being conducted that a lower pacemaker takes over, leading to an escape junctional, subjunctional, or ventricular rhythm with a slow regular R-R interval for two or more cycles.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of an accelerated lower pacemaker (due, eg, to triggered activity causing an accelerated junctional rhythm) with regularization of the R-R intervals, in contrast to the irregularly irregular intervals in atrial fibrillation, strongly suggests
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity. Simply palpating the peripheral pulse in this setting may lead to the erroneous assumption that the patient has converted to sinus rhythm; however, the ECG will continue to show fibrillatory waves [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         More rarely, the lower pacemaker may be regular but there is a Wenckebach type of exit block, resulting in decreasing R-R intervals with group beating characteristic of the Wenckebach phenomenon. Casual evaluation of such a patient who might have severe
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity may lead to the mistaken conclusion that the irregular rhythm is due to persistent atrial fibrillation and the digoxin may be continued or the dose increased. (See
         <a class="medical medical_review" href="/z/d/html/909.html" rel="external">
          "Second-degree atrioventricular block: Mobitz type I (Wenckebach block)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Even less commonly, impulses from the lower pacemaker travel alternately down the right and left bundle branches, resulting in a bidirectional ventricular tachycardia  (
         <a class="graphic graphic_waveform graphicRef71796" href="/z/d/graphic/71796.html" rel="external">
          waveform 7
         </a>
         ). (See
         <a class="local">
          'Bidirectional ventricular tachycardia'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24718286">
         <span class="h2">
          Junctional rhythm, tachycardia, and bradycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         AV junctional rhythms are sometimes a sign of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity. Digoxin toxicity can result in varying degrees of AV block that may allow the appearance of junctional escape beats and escape junctional (or atrioventricular nodal) rhythms. The junctional rate may be normal (40 to 60 beats/min), accelerated (60 to 120 beats/min, due to direct effects or adrenergic influences), or depressed (less than 40 beats/min, due to enhanced vagal tone, dysfunctional pacemakers in organic heart disease, or to hyperkalemia caused by the digoxin toxicity) [
         <a href="#rid5">
          5,20,21,37
         </a>
         ].
        </p>
        <p>
         The QRS complex is usually narrow with junctional rhythms, since the pacemaker is typically above the bifurcation of the bundle branches. However, the QRS may be wide if there is a conduction disturbance distal to the pacemaker, a dominant subjunctional pacemaker, or a dominant ventricular pacemaker.
        </p>
        <p class="headingAnchor" id="H24718293">
         <span class="h2">
          Ventricular arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of ventricular arrhythmias may result from
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity, including premature ventricular complexes (PVCs), ventricular tachycardia, and ventricular fibrillation.
        </p>
        <p class="headingAnchor" id="H24718559">
         <span class="h3">
          Premature ventricular complexes
         </span>
         <span class="headingEndMark">
          —
         </span>
         PVCs, often the first sign of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity, are also the most common arrhythmia due to digoxin toxicity. While isolated PVCs may be seen, the PVCs often appear in a bigeminal pattern  (
         <a class="graphic graphic_waveform graphicRef72547" href="/z/d/graphic/72547.html" rel="external">
          waveform 8
         </a>
         ). Although ventricular bigeminy can result from organic heart disease, it should raise the suspicion of digoxin intoxication in relevant contexts.
        </p>
        <p class="headingAnchor" id="H24718566">
         <span class="h3">
          Ventricular tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to reentry or possibly to triggered membrane activity (delayed afterdepolarizations), ventricular tachycardia (VT) can be induced by
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         excess [
         <a href="#rid30">
          30
         </a>
         ]. With triggered membrane activity, VT may be resistant to interruption by ventricular pacing since the faster rate of pacing may in itself increase the transient inward current and worsen the arrhythmia. The axis and width of the QRS complex on the ECG are determined by the site of origin of the VT, which may be in the specialized fascicles.
        </p>
        <p class="headingAnchor" id="H24718573">
         <span class="h3">
          Ventricular fibrillation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ventricular fibrillation (VF) can occur with
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity, but is usually a late rhythm. VF can, however, be induced by the use of electric cardioversion in patients with an atrial tachyarrhythmia associated with excess digoxin [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24718477">
         <span class="h3">
          Bidirectional ventricular tachycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         An unusual arrhythmia is the so-called "bidirectional" ventricular tachycardia in which the rhythm is regular but every other beat has a different axis as it travels alternately down different conduction pathways  (
         <a class="graphic graphic_waveform graphicRef71796" href="/z/d/graphic/71796.html" rel="external">
          waveform 7
         </a>
         ). In most cases, the rhythm has a right bundle branch block morphology with an alternating left and right axis [
         <a href="#rid39">
          39
         </a>
         ]. However, alternating right and left bundle branch patterns may be seen. Bidirectional ventricular tachycardia may be confused with ventricular bigeminy. In true bigeminy, the ventricular beat in the bigeminal pattern is premature. By comparison, the R-R interval is regular with a bidirectional tachycardia, since all of the beats arise from a single focus.
        </p>
        <p>
         Bidirectional ventricular tachycardia is not specific for
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         intoxication. It is a frequent finding in familial catecholaminergic polymorphic VT, a much less common disorder [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24718580">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background
         </strong>
         – Arrhythmias resulting from
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity are potentially life threatening; they are seen in up to 5 percent of patients receiving digoxin (or digitoxin). The incidence of digoxin toxicity has declined over time due to appropriate dose reductions in patients with renal dysfunction, more accurate methods for measuring plasma digoxin levels, and the availability of other medications for the treatment of chronic heart failure and tachyarrhythmias leading to a reduced reliance on digoxin. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Incidence of digoxin toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         <strong>
          levels
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Trough levels –
         <strong>
         </strong>
         Maintaining trough serum
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         concentration levels at a lower therapeutic range (eg, between 0.5 and 0.8 ng/mL [0.6 to 1.0 nmol/L]) is recommended to help minimize toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Life-threatening digoxin-induced arrhythmias occur at substantially increased frequency as the plasma
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         concentration rises above 2.0 ng/mL (2.6 nmol/L). However, signs of toxicity may occur at much lower plasma levels, especially in the presence of comorbid conditions (eg, electrolyte abnormalities, myocardial ischemia, older age with heart failure).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypokalemia is a particularly important risk factor that can promote digoxin-induced arrhythmias even if the
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         concentration is thought to be within the "therapeutic" range. (See
         <a class="local">
          'Incidence of digoxin toxicity'
         </a>
         above and
         <a class="local">
          'Plasma digoxin levels associated with toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Digoxin-induced arrhythmias
         </strong>
         – A wide range of arrhythmias occurring at almost any intracardiac location can be seen with
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity, depending in part upon the age of the patient and the state of the myocardium. Accentuation of vagal effects and resulting bradyarrhythmias is more commonly seen in younger, healthier individuals. Conversely, patients with severe cardiac disease and concurrent digoxin toxicity are more susceptible to ventricular ectopy and tachyarrhythmias. (See
         <a class="local">
          'Digoxin-induced arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Paroxysmal atrial tachycardia
         </strong>
         – This arrhythmia results from toxic levels of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         that cause ectopic atrial tachycardia, often with 2:1 atrioventricular (AV) block  (
         <a class="graphic graphic_waveform graphicRef56994" href="/z/d/graphic/56994.html" rel="external">
          waveform 2
         </a>
         ). This electrocardiographic (ECG) pattern is strongly suggestive of digoxin toxicity in patients on the drug. Contrary to its name, the arrhythmia is not typically paroxysmal when induced by digoxin; rather, it is a persistent arrhythmia until specific therapy is instituted or digoxin levels fall below the toxic range. (See
         <a class="local">
          'Ectopic atrial tachycardia with block'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Atrial fibrillation or atrial flutter
         </strong>
         –
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         toxicity can occur in patients with atrial fibrillation or flutter, even though these arrhythmias are rarely caused by digoxin. The ECG findings vary with increasing degrees of digoxin toxicity and with the possible presence of block above or below the pacemaker  (
         <a class="graphic graphic_waveform graphicRef64396 graphicRef76154 graphicRef55119 graphicRef66940" href="/z/d/graphic/64396.html" rel="external">
          waveform 3A-D
         </a>
         ). (See
         <a class="local">
          'Atrial fibrillation and flutter'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          AV block and junctional rhythms
         </strong>
         –
         <strong>
         </strong>
         These are frequently a sign of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity. Digoxin toxicity can result in varying degrees of AV block  (
         <a class="graphic graphic_waveform graphicRef67882" href="/z/d/graphic/67882.html" rel="external">
          waveform 4
         </a>
         and
         <a class="graphic graphic_waveform graphicRef73051" href="/z/d/graphic/73051.html" rel="external">
          waveform 5
         </a>
         and
         <a class="graphic graphic_waveform graphicRef72863" href="/z/d/graphic/72863.html" rel="external">
          waveform 6
         </a>
         ). (See
         <a class="local">
          'Atrioventricular nodal block'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         This AV block may allow the appearance of junctional escape beats and escape junctional (or AV nodal) rhythms. Depending on other factors such as adrenergic or vagal tone, the junctional rate may be normal (40 to 60 beats/min), accelerated (60 to 120 beats/min), or depressed (less than 40 beats/min). (See
         <a class="local">
          'Junctional rhythm, tachycardia, and bradycardia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ventricular arrhythmias
         </strong>
         –
         <strong>
         </strong>
         A variety of ventricular arrhythmias may result from
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity, including premature ventricular complexes (PVCs), ventricular tachycardia, and ventricular fibrillation. (See
         <a class="local">
          'Ventricular arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         PVCs are often the first sign of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         toxicity and are the most common arrhythmia due to digoxin toxicity. PVCs can be isolated or occur in a bigeminal pattern  (
         <a class="graphic graphic_waveform graphicRef72547" href="/z/d/graphic/72547.html" rel="external">
          waveform 8
         </a>
         ). Although ventricular bigeminy can result from organic heart disease, it should raise the suspicion of digoxin intoxication. (See
         <a class="local">
          'Premature ventricular complexes'
         </a>
         above.).
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation 2004; 109:2959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauptman PJ, Kelly RA. Digitalis. Circulation 1999; 99:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angraal S, Nuti SV, Masoudi FA, et al. Digoxin Use and Associated Adverse Events Among Older Adults. Am J Med 2019; 132:1191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussain Z, Swindle J, Hauptman PJ. Digoxin use and digoxin toxicity in the post-DIG trial era. J Card Fail 2006; 12:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahdyoon H, Battilana G, Rosman H, et al. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988. Am Heart J 1990; 120:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williamson KM, Thrasher KA, Fulton KB, et al. Digoxin toxicity: an evaluation in current clinical practice. Arch Intern Med 1998; 158:2444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           See I, Shehab N, Kegler SR, et al. Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010. Circ Heart Fail 2014; 7:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ambrosy AP, Pang PS, Gheorghiade M. Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated. JACC Heart Fail 2016; 4:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005; 46:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed A, Pitt B, Rahimtoola SH, et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol 2008; 123:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberger ZD, Goldberger AL. Therapeutic ranges of serum digoxin concentrations in patients with heart failure. Am J Cardiol 2012; 109:1818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Washam JB, Stevens SR, Lokhnygina Y, et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet 2015; 385:2363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen LA, Fonarow GC, Simon DN, et al. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol 2015; 65:2691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992; 69:108G.
          </a>
         </li>
         <li class="breakAll">
          Eisner DA, Smith TW. The Na-K pump and its effectors in cardiac muscle. In: The Heart and Cardiovascular System, Fozzard HA, Haber E, Katz AM, Morgan HE (Eds), Raven Press, New York 1991. p.863.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagawa T, Sagawa K, Kelly JE, et al. Activation of cardiac ryanodine receptors by cardiac glycosides. Am J Physiol Heart Circ Physiol 2002; 282:H1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe AM. Digitalis and the autonomic nervous system. J Am Coll Cardiol 1985; 5:35A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toda N, West TC. The influence of ouabain on cholinergic responses in the sinoatrial node. J Pharmacol Exp Ther 1966; 153:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodman DJ, Rossen RM, Ingham R, et al. Sinus node function in the denervated human heart. Effect of digitalis. Br Heart J 1975; 37:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith TW, Antman EM, Friedman PL, et al. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis 1984; 26:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith TW, Antman EM, Friedman PL, et al. Digitalis glycosides: mechanisms and manifestations of toxicity. Part II. Prog Cardiovasc Dis 1984; 26:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiffel JA, Bigger JT Jr, Cramer M. Effects of digoxin on sinus nodal function before and after vagal blockade in patients with sinus nodal dysfunction: a clue to the mechanisms of the action of digitalis on the sinus node. Am J Cardiol 1979; 43:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vassalle M, Greenspan K, Hoffman BF. An Analysis of Arrhythmias Induced by Ouabain in Intact Dogs. Circ Res 1963; 13:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James TN, Nadeau RA. The chronotropic effect of digitalis studied by direct perfusion of the sinus node. J Pharmacol Exp Ther 1963; 139:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherlag BJ, Abelleira JL, Narula OS, Samet P. The differential effects of ouabain on sinus, A-V nodal, His bundle, and idioventricular rhythms. Am Heart J 1971; 81:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendez C, Aceves J, Mendez R. Inhibition of adrenergic cardiac acceleration by cardiac glycosides. J Pharmacol Exp Ther 1961; 131:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinbeck G, Bonke FI, Allessie MA, Lammers WJ. The effect of ouabain on the isolated sinus node preparation of the rabbit studied with microelectrodes. Circ Res 1980; 46:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takayanagi K, Jalife J. Effects of digitalis intoxication on pacemaker rhythm and synchronization in rabbit sinus node. Am J Physiol 1986; 250:H567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geer MR, Wagner GS, Waxman M, Wallace AG. Chronotropic effect of acetylstrophanthidin infusion into the canine sinus nodal artery. Am J Cardiol 1977; 39:684.
          </a>
         </li>
         <li class="breakAll">
          Gorgels APM, Vos MA, Smeets JLRM, et al. Delayed afterdepolarizations and atrial and ventricular arrhythmias. In: Cardiac Electrophysiology: A Textbook, Rosen MR, Janse MJ, Wit AL (Eds), Futura Publishing, Mount Kisco 1990. p.341.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastor JA, Yurchak PM. Recognition of digitalis intoxication in the presence of atrial fibrillation. Ann Intern Med 1967; 67:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carleton RA, Miller PH, Graettinger JS. Effects of ouabain, atropine, and ouabain and atropine on A-V nodal conduction in man. Circ Res 1967; 20:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toda N, West TC. The action of ouabain on the function of the atrioventricular node in rabbits. J Pharmacol Exp Ther 1969; 169:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodman DJ, Rossen RM, Cannom DS, et al. Effect of digoxin on atioventricular conduction. Studies in patients with and without cardiac autonomic innervation. Circulation 1975; 51:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricci DR, Orlick AE, Reitz BA, et al. Depressant effect of digoxin on atrioventricular conduction in man. Circulation 1978; 57:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Childers R. Classification of cardiac dysrhythmias. Med Clin North Am 1976; 60:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisch C, Knoebel SB. Digitalis cardiotoxicity. J Am Coll Cardiol 1985; 5:91A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleiger R, Lown B. Cardioversion and digitalis. II. Clinical studies. Circulation 1966; 33:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris SN, Zipes DP. His bundle electrocardiography during bidirectional tachycardia. Circulation 1973; 48:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106:69.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 944 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15210613" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Digoxin in the management of cardiovascular disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10069797" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Digitalis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31077654" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Digoxin Use and Associated Adverse Events Among Older Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16762795" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Digoxin use and digoxin toxicity in the post-DIG trial era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2239670" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9855382" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Digoxin toxicity: an evaluation in current clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24300242" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27126283" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16053964" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17382417" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22502901" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Therapeutic ranges of serum digoxin concentrations in patients with heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25749644" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26112191" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1626485" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Recognition and management of digitalis toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1626485" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Recognition and management of digitalis toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11834511" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Activation of cardiac ryanodine receptors by cardiac glycosides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3886751" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Digitalis and the autonomic nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5921349" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The influence of ouabain on cholinergic responses in the sinoatrial node.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1096907" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Sinus node function in the denervated human heart. Effect of digitalis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6371896" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Digitalis glycosides: mechanisms and manifestations of toxicity. Part I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6326196" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Digitalis glycosides: mechanisms and manifestations of toxicity. Part II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/433782" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Effects of digoxin on sinus nodal function before and after vagal blockade in patients with sinus nodal dysfunction: a clue to the mechanisms of the action of digitalis on the sinus node.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14047639" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : An Analysis of Arrhythmias Induced by Ouabain in Intact Dogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13957262" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The chronotropic effect of digitalis studied by direct perfusion of the sinus node.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5539548" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The differential effects of ouabain on sinus, A-V nodal, His bundle, and idioventricular rhythms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13769367" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Inhibition of adrenergic cardiac acceleration by cardiac glycosides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7357695" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The effect of ouabain on the isolated sinus node preparation of the rabbit studied with microelectrodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3963214" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effects of digitalis intoxication on pacemaker rhythm and synchronization in rabbit sinus node.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/857629" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Chronotropic effect of acetylstrophanthidin infusion into the canine sinus nodal artery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/857629" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Chronotropic effect of acetylstrophanthidin infusion into the canine sinus nodal artery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4860764" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Recognition of digitalis intoxication in the presence of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6025609" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Effects of ouabain, atropine, and ouabain and atropine on A-V nodal conduction in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5824610" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The action of ouabain on the function of the atrioventricular node in rabbits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1089491" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Effect of digoxin on atioventricular conduction. Studies in patients with and without cardiac autonomic innervation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/346256" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Depressant effect of digoxin on atrioventricular conduction in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/54514" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Classification of cardiac dysrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3886755" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Digitalis cardiotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5940516" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Cardioversion and digitalis. II. Clinical studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4781244" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : His bundle electrocardiography during bidirectional tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093772" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
